Elbit Real Est risk analysis
Elbit Real Est (EMITF) Risk Analysis
Risk Overview Q4, 2018
Source: the company's latest filing for the period ended Dec 31, 2018, filed May 13, 2019
Risk Change Over Time
No filing history is available.
- Share Price & Shareholder Rights - Risk 1Insightec's ability to initiate an IPO requires the consent of the holders of its preferred shares.
Following the completion of Insightec's Series E investment round during 2018, Insightec's shareholders approved certain amendments to Insightec's Article of Association, including that prior to December 27, 2021, initiating an initial public offering of capital stock of Insightec pursuant to an effective registration statement 41 under the Securities Act, or pursuant to similar laws in any other jurisdiction other than a Qualified IPO is subject to the approval of the holders of at least 66% of the Series E Preferred Shares then issued and outstanding. In addition, initiating an initial underwritten primary public offering of capital stock of Insightec pursuant to an effective registration statement under the Securities Act, or pursuant to similar laws in any other jurisdiction, other than a Qualified IPO is subject to the approval of the holders of at least 85% of the Preferred Shares voting together as a single class on an as converted basis. Qualified IPO is defined as the initial underwritten public offering pursuant to an effective registration statement under the Securities Act or similar laws in effect in the State of Israel that (i) raises at least $75.0 million of gross proceeds, (ii) public offering which will result in the Ordinary Shares being listed either on the New York Stock Exchange or NASDAQ; and (iii) if such public offering were to occur prior to December 27, 2021, then such public offering would result in a per share issue price of not less than $4.02 per Ordinary Share ("Qualified IPO"). For more information regarding InSightec's Article of Association see "Item 4B – Business Overview – Insightec – Holdings in InSightec's shares".
- Share Price & Shareholder Rights - Risk 2Our ordinary shares have been delisted from trading on Nasdaq.
On February 7, 2019, the Company announced that NASDAQ had informed the Company that the Hearings Panel has determined to delist the Company's ordinary shares. Nasdaq subsequently suspended Company from trading shares on Nasdaq effective at the open of business on February 11, 2019 and filed a Form 25 (Notification of Removal from Listing) with the SEC after applicable appeal periods lapsed to notify the SEC of the delisting of the Company's ordinary shares, effective at the opening of the trading session on May 13, 2019. Nasdaq had previously informed the Company that it did not meet Nasdaq Listing Rule 5450(b)(3)(C) (under which the Company must maintain a minimum market value of its publicly held shares of $15,000,000 for 30 consecutive business days), and that the Company would be subject to delisting if such requirements were not met within a certain time period. The Company's ordinary shares continue to be listed on the Tel Aviv Stock Exchange, and its ordinary shares are currently quoted on the OTC Markets. As a result of the delisting from Nasdaq, an investor may find it significantly more difficult to dispose of, or to obtain accurate quotations as to the value of, our shares, and our ability to raise future capital through the sale of our shares will be adversely affected. Moreover, we are unable to use the SEC's "short form" Form F-3 to register the offering and sale of securities, even for limited primary offerings. In addition, we are required to comply with enhanced reporting obligations under the Israeli securities laws, in addition to the reporting obligations under the U.S. securities laws, which could require additional management attention, increase our legal and accounting expenses and raise our exposure to sanctions for possible violations of Israeli securities laws.
- Debt & Financing - Risk 3We granted a vendor loan of approximately €8 million to the purchaser of the Radisson Hotel, and if the purchaser doesn't repay the loan, it may be a material adverse effect on our projected cash flow.
On December 19, 2017, we announced that we completed the sale of our holdings in a SPV that held the Radisson Hotel Complex in Bucharest, Romania. As part of the transaction we granted the purchaser an €8 million vendor loan for a term of three years, bearing interest at a rate of 5% per annum. The loan was given as collateral for customary post-closing liabilities of the SPV, whereby the purchaser may offset adjudicated losses which may be incurred by it as a result of a breach of warranties or in respect of certain indemnities given under the agreement. On April 2, 2018 we announced that we received a notice from the purchaser claiming that it is entitled to indemnification in the amount of approximately €3 million, due to the alleged breach of certain warranties made by the Subsidiary in the Agreement (the "Notice"). In the Notice the purchaser has informed the Company that it has submitted claims under the policies of Warranty & Indemnity Insurance and Title Insurance taken out in terms of the agreement, which provides that where loss arising from a warranty claim may reasonably be anticipated to be covered by such insurance policies, the purchaser will firstly attempt to recover such loss out of the proceeds paid out under such policies. The Company is currently examining the Notice with its legal advisors. After a preliminary review of the Notice, the Company believes that the warranty claims are without merit and intends to vigorously contest same. See–"Item 4 - Information on the Company – History and Development of the Company – Recent Events Sale of our holdings in the Radisson complex in Bucharest, Romania" If the SPV fails to pay the loan under any circumstances (such as a result of a breach of warranties or certain indemnities given under the agreement), it may be a material adverse effect on our projected cash flow.
- Corporate Activity and Growth - Risk 4We may have difficulties in realization of the sale of the plot in Bangalore, India; or alternatively we may have difficulties exercising a full separation from the buyer of the plot in Bangalore, India
Our strategy with respect to our plots in India is to dispose of such assets under the most optimal market conditions. Due to regulatory, physical and other limitations to develop our project in Bangalore, India, on December 2, 2015, we announced that EPI signed an agreement to sell 100% of its interest in a special purpose vehicle which holds a plot in Bangalore, India to a local Investor (the "Purchaser") which should had been closed on September 30, 2016. The Purchaser has failed to close the transaction in the agreed time line. As a result of this breach, the Purchaser was required to carry out an agreed upon separation mechanism in such manner that EPI will have full title over the plot. Such mechanism include mainly the execution of certain title documents transferring and duly registering the 10% undivided interest in the plot that are being held by the Purchaser in EPI's favor. Since the separation mechanism has not been executed by the Purchaser, EPI has received from the escrow agent, the sale deeds and transfer documents for land plots covering approximately 8.7 acres which had been mortgaged by the Purchaser under the agreement. On June 19, 2017, we announced that EPI has signed a revised agreement for the sale of the plot in Bangalore to the Purchaser. As part of the agreement, part of the consideration will be paid by the Purchaser in installments until the final closing that was set to take place on September 1, 2018. All other existing securities granted to EPI under the previous agreement will remain in place until the final closing. In January 2018, the Purchaser has notified EPI that due to a proposed zoning change (initiated by the Indian authorities) which could potentially impact the development of the land, all remaining payments under the Agreement will be stopped until a mutually acceptable solution is reached on this matter. EPI has rejected the Purchaser's claims, having no relevance to the existing Agreement, and started to evaluate its legal options. INR 46 Crores (approximately EUR 6.06 million) were paid till March 2018. In March 2018, an amended revised agreement was signed, and the Purchaser and EPI have agreed that the total purchase price shall be increased to INR 350 Crores (approximately €44.5 million). The Final Closing will take place on 31 August 2019 when the final installment of circa INR 212 Crores (approximately EUR 26.9 million) will be paid to EPI against the transfer of the outstanding share capital of the SPV. On February 4, 2019, the Company announced that the Purchaser defaulted on payments and EPI is considering all legal measures available to it to protect its interest. During March 2019, the Company announced that the Purchaser has further paid INR 9.25 Crores (approximately €1.15 million). During April 2019 EPI has reached an understanding with the Purchaser according to which: (i) the closing date for the transaction will be extended to November 2019 (instead of August 2019) (the "Closing Date"); and (ii) the consideration will be increased to approximately €45.64 (INR 356 crores) (instead of INR 350 crores) (the "Consideration"). The Closing Date can be further extended to August 2020, subject to mutually agreed payment terms. On May 13, 2019, the Company announced that the Purchaser defaulted on payments of INR 10 crores (approximately €1.27 million) according to the new understandings signed on April 2019. EPI has initiated legal process to protect its interest while it continues to negotiate with the Purchaser for payment of the amount due. As of the date of this report, the Purchaser paid in total INR 80 crores (approximately EUR 10.26 million) as against INR 90 crores (approximately EUR 11.5 million) that was supposed to be paid by end of April 2019 according to the mutual understating. If the Purchaser defaults before the final closing, EPI is entitled to forfeit the amounts paid by the Purchaser until this date (approximately €10.26 million) as stipulated in the revised agreement. All other existing securities granted to EPI under the previous agreements will remain in place until the final closing. However, it should be noted that, in case of a breach by the Purchaser of the new agreement, we will still should achieve full separation from the Purchaser, which might be a long and tedious process and we are not certain that we will be able to achieve it. In case such separation would not be achieved it may cause a significant impairment to the value of the property and may cause significant difficulties to find another third-party buyer to this plot taking into account that there is no clean title on the property. This may have a material adverse effect on our operations, cash flow and in turn, our ability to repay our debts in timely manner. Even if we are able to properly execute the separation mechanism (in particular with respect to the transfer of the Purchaser's 10% undivided interest in our favor) and/or exercise the guarantees placed by the Purchaser, there is no guarantee that we will be able to dispose of the land in the Bangalore project to a third party on efficient economic terms due to proprietary claims to certain parts of the Bangalore project, and other third party holdings on parts of the land within the Bangalore project thus making the holdings in the land a non-contiguous property. In addition, legal and regulatory restrictions placed by local authorities can materially impede our ability to dispose of the land on optimal commercial terms which may materially adversely affect our ability to dispose of the land to third parties which may jeopardize our business strategy, planning and operations, and could cause severe delays in disposition of the plots and could have a material adverse effect on our operations, cash flow and in turn, our ability to repay our debts in timely manner.
- Corporate Activity and Growth - Risk 5We may have difficulties in realization of the sale of the plot in Chennai, India; or alternatively we may have difficulties exercising a full separation from the buyer of the plot in Chennai, India
Our strategy in respect of our projects in India is to liquidate our assets at the most commercially optimal prices. However, in 2016 we have entered into a Joint Development Agreement ("JDA") transaction with a local developer (the "Developer") in order to develop our project in Chennai, India. See "Item 4 - Information on the Company – History and Development of the Company – Recent Events – Joint Development Agreement and Term Sheet with respect to our Plot in Chennai, India". On July 5, 2018, due to delays in the commencement of the project, we announced that EPI signed a term sheet with the Developer in respect to the sale of the SPV which holds our project in Chennai, India. Under the terms of the term sheet the Developer is to purchase the SPV in consideration for €13.8 million, subject to adjustment with respect to the previous amount deposited and the existing cash in the SPV. In the period of time following the signing of the term sheet EPI and the Developer agreed on: (i) updating the consideration (following a due diligence) to €13.2 million; (ii) the local developer will pay EPI an additional consideration that will be calculated as an annual interest of 12% on the consideration amount (calculated from December 1, 2018 till the closing date; (iii) several postponement of the closing date. On January 14, 2019, we announced that EPI has granted the Developer until mid-February 2019, to complete the transaction. However, On February 11, 2019, we announced that the Developer has defaulted to complete the transaction and EPI has terminated the JDA and the Term Sheet with the Developer. On March 4, 2019, we announced that the SPV (a subsidiary of EPI) holding the plot in Chennai has initiated an arbitration proceeding against the Developer in accordance with the Arbitration Rules of the Singapore International Arbitration Center (as required by the agreement between the parties). The reliefs sought in the framework of the arbitration are as follows: (a) a declaration that the JDA stands terminated validly; and (b) to instruct the Developer to compensate for damages caused due to the breach of the Joint Development Agreement by the Developer. Even though we announced the termination of the term sheet and the JDA and initiated the arbitration process, we still should achieve full separation from him, which might be a long and tedious process and we are not certain that we will be able to achieve it. In case such separation would not be achieved it may cause a significant impairment to the value of the property and may cause significant difficulties to find another third-party buyer to this plot since new buyer would likely to ask that we terminate our JDA with the Developer, which is possible only under certain events detailed in the JDA. This may have a material adverse effect on our operations, cash flow and in turn, our ability to repay our debts in timely manner.
Risk Highlights Q4, 2018
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 60
- Share Price & Shareholder Rights - Risk 1AddedInsightec's ability to initiate an IPO requires the consent of the holders of its preferred shares.
Following the completion of Insightec's Series E investment round during 2018, Insightec's shareholders approved certain amendments to Insightec's Article of Association, including that prior to December 27, 2021, initiating an initial public offering of capital stock of Insightec pursuant to an effective registration statement 41 under the Securities Act, or pursuant to similar laws in any other jurisdiction other than a Qualified IPO is subject to the approval of the holders of at least 66% of the Series E Preferred Shares then issued and outstanding. In addition, initiating an initial underwritten primary public offering of capital stock of Insightec pursuant to an effective registration statement under the Securities Act, or pursuant to similar laws in any other jurisdiction, other than a Qualified IPO is subject to the approval of the holders of at least 85% of the Preferred Shares voting together as a single class on an as converted basis. Qualified IPO is defined as the initial underwritten public offering pursuant to an effective registration statement under the Securities Act or similar laws in effect in the State of Israel that (i) raises at least $75.0 million of gross proceeds, (ii) public offering which will result in the Ordinary Shares being listed either on the New York Stock Exchange or NASDAQ; and (iii) if such public offering were to occur prior to December 27, 2021, then such public offering would result in a per share issue price of not less than $4.02 per Ordinary Share ("Qualified IPO"). For more information regarding InSightec's Article of Association see "Item 4B – Business Overview – Insightec – Holdings in InSightec's shares".
- Share Price & Shareholder Rights - Risk 2AddedOur ordinary shares have been delisted from trading on Nasdaq.
On February 7, 2019, the Company announced that NASDAQ had informed the Company that the Hearings Panel has determined to delist the Company's ordinary shares. Nasdaq subsequently suspended Company from trading shares on Nasdaq effective at the open of business on February 11, 2019 and filed a Form 25 (Notification of Removal from Listing) with the SEC after applicable appeal periods lapsed to notify the SEC of the delisting of the Company's ordinary shares, effective at the opening of the trading session on May 13, 2019. Nasdaq had previously informed the Company that it did not meet Nasdaq Listing Rule 5450(b)(3)(C) (under which the Company must maintain a minimum market value of its publicly held shares of $15,000,000 for 30 consecutive business days), and that the Company would be subject to delisting if such requirements were not met within a certain time period. The Company's ordinary shares continue to be listed on the Tel Aviv Stock Exchange, and its ordinary shares are currently quoted on the OTC Markets. As a result of the delisting from Nasdaq, an investor may find it significantly more difficult to dispose of, or to obtain accurate quotations as to the value of, our shares, and our ability to raise future capital through the sale of our shares will be adversely affected. Moreover, we are unable to use the SEC's "short form" Form F-3 to register the offering and sale of securities, even for limited primary offerings. In addition, we are required to comply with enhanced reporting obligations under the Israeli securities laws, in addition to the reporting obligations under the U.S. securities laws, which could require additional management attention, increase our legal and accounting expenses and raise our exposure to sanctions for possible violations of Israeli securities laws.
- Share Price & Shareholder Rights - Risk 3ChangedIf Elbit Medical defaults on its obligations to the holders of its convertible notes, the holders may foreclose on Elbit Medical's holdings in InSightec and Gamida.
As described above, on February 19, 2018, we announced that Elbit Medical completed a public offering of notes with a principal amount of NIS 180 million convertible into ordinary shares of Elbit Medical. The notes bear annual interest at 5% in the first two years and 10% in the remaining period and are convertible into Elbit Medical ordinary share. The trust agreement of the notes includes certain limitations, including on the ability of Elbit Medical to distribute dividends and raise additional debt. In addition, the notes are secured by a pledge on a portion of Elbit Medical's holdings in InSightec and Gamida in a "value to loan" ratio of 200% (as of the issuance date of the notes). In the event Elbit Medical defaults on its obligations to the holders of its convertible notes, the holders may foreclose on Elbit Medical's holdings in Insightec and Gamida, which would have a material adverse effect on our business.
- Share Price & Shareholder Rights - Risk 4ChangedIf Elbit Medical does not satisfy the applicable stock exchange conditions for continued listing, its shares could be delisted from the Tel Aviv Stock Exchange.
The shares of our subsidiary Elbit Medical Technologies Ltd. are listed on the Tel-Aviv Stock Exchange under the symbol "EMTC". If Elbit Medical Technologies Ltd. do not satisfy the conditions of the stock exchange for continued listing (such as, but not limited to, free-float requirements), its shares could be delisted. Such occurrences would make the realization of this investment or any part thereof by us more difficult and could limit the possibility to attract new investors to this portfolio.
- Share Price & Shareholder Rights - Risk 5We have no controlling shareholders who are able to influence the composition of our Board of Directors.
Our largest shareholders include affiliates of York Capital Management Global Advisers LLC and affiliates of Davidson Kempner Capital Management LP who beneficially own an aggregate of approximately 18.9% and 14.3% respectively, of our outstanding ordinary shares. To our knowledge, these shareholders are not party to a shareholders' agreement between them or with any other shareholders. As a result, we have no controlling shareholder able to influence the composition of our Board of Directors. Consequently, following the next annual general meeting of our shareholders, a Board of Directors comprised of new individuals may be elected. Such new Board of Directors may have significantly different corporate strategies than our current Board of Directors, which may cause a material change in our operations and financial results.
- Share Price & Shareholder Rights - Risk 6The market price of our ordinary shares may suffer from fluctuation and may decline significantly.
There are a number of different major groups of shareholders with different and possibly opposing interests who may at any time sell their shares in the Company. There may be an adverse effect on the market price of our shares as a result of a substantial number of shares being sold or available for sale. Our ordinary shares are generally freely tradable, and the potential sales of such shares could cause the market price of our ordinary shares to decline significantly. This might also make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.
- Share Price & Shareholder Rights - Risk 7If the convertible notes issued by Elbit Medical are converted into ordinary shares of Elbit Medical, our holdings in Elbit Medical will be diluted.
On February 19, 2018, we announced that Elbit Medical completed a public offering of notes with a principal amount of NIS 180 million convertible into ordinary shares of Elbit Medical. The notes bear annual interest at 5% in the first two years and 10% in the remaining period and are convertible at any time until the maturity date of the notes, March 1, 2022, at a price per Elbit Medical ordinary share equal to NIS 1.47 in notes. In the event the entire principal amount of the convertible notes is converted into Elbit Medical ordinary shares, our holdings in Elbit Medical will be diluted and assuming no additional ordinary shares are issued by Elbit Medical, our holdings in Elbit Medical will be reduced to 41% of the issued share capital of Elbit Medical. In addition, the price per ordinary share of Elbit Medical may decline as a result of the issuance of a significant number of shares.
- Share Price & Shareholder Rights - Risk 8Provisions of Israeli law may delay, prevent or make more difficult a merger or other business combination, which may depress our share price.
Provisions of Israeli corporate law may have the effect of delaying, preventing or making more difficult a merger or acquisition involving us. The Companies Law generally provides that a merger be approved by the board of directors and a majority of the shares present and voting on the proposed merger. For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares not held by the other party to the merger (or by any person who holds 25% or more of the shares or the right to appoint 25% or more of the directors of the other party or its general manager) have voted against the merger. Upon the request of any creditor of a party to the proposed merger, a court may delay or prevent the merger if it concludes that there is a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the surviving company. Finally, a merger may not be completed unless at least (i) 50 days have passed since the filing of a merger proposal signed by both parties with the Israeli Registrar of Companies and (ii) 30 days have passed since the merger was approved by the shareholders of each merging company. The Companies Law also provides that an acquisition of shares of a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become (i) a 25% or greater shareholder of the company unless prior to such acquisition there is already another 25% or greater shareholder of the company or (ii) a 45% or greater shareholder of the company unless prior to such acquisition there is already a 45% or greater shareholder of the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder approval or (ii) was from a 25% or 45% shareholder, as the case may be. The tender offer may be consummated only if (i) at least 5% of the company's outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer. In addition, under our amended articles of association, a person seeking to cross the 25% ownership threshold is required to offer to purchase at least 10% of our outstanding ordinary shares in such a tender offer. In any event, if as a result of an acquisition of shares the purchaser will beneficially own more than 90% of a company's shares, the acquisition must be made by means of a tender offer for all of the remaining shares. Shareholders may request an appraisal in connection with a tender offer for a period of six months following the consummation of the tender offer, but the purchaser is entitled to stipulate that any tendering shareholder surrender its appraisal rights. Finally, Israel tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges its ordinary shares for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock swap. The described restrictions could prevent or make more difficult an acquisition involving us, which could depress our share price
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

